SC
DMII

Sculptor Capital’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Sculptor Capital’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.99M Hold
500,000
– – 0.05% 180
2025
Q4 		$4.95M Buy
+500,000
New +$4.94M 0.05% 199

Other funds holding DMII

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Sculptor Capital's DMII Position: Q1 2026 in Review

Sculptor Capital held its Drugs Made In America Acquisition II Corp (DMII) position steady in Q1 2026 at 500,000 shares worth $4.99M. The position accounts for 0.05% of the portfolio, ranked #180.

Sculptor Capital first reported a position in DMII in Q4 2025 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • Sculptor Capital held 500,000 shares of Drugs Made In America Acquisition II Corp worth $4.99M as of Q1 2026.
  • Sculptor Capital left its Drugs Made In America Acquisition II Corp share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition II Corp made up 0.05% of Sculptor Capital's portfolio in Q1 2026, its #180 holding.
  • Sculptor Capital first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.